Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT07445503

High Phenolic Olive Oil for Enhancing Metabolic Health: a Randomized-controlled Trial in Patients With cEntral Obesity (HOPE)

Led by University of Peloponnese · Updated on 2026-03-03

80

Participants Needed

1

Research Sites

112 weeks

Total Duration

On this page

Sponsors

U

University of Peloponnese

Lead Sponsor

H

Harokopio University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Olive oil is a fundamental component of the Mediterranean diet and a major source of monounsaturated fatty acids with well-established cardioprotective properties. When rich in phenolic compounds-such as hydroxytyrosol, tyrosol, oleuropein, oleocanthal, oleacein, and ligstroside aglycone-it is considered a functional food with antioxidant, anti-inflammatory, cardioprotective, chemoprotective, and neuroprotective effects. According to EU Regulation 432/2012, daily consumption of 20 g of extra virgin olive oil containing at least 5 mg of hydroxytyrosol and tyrosol derivatives (250 mg/kg) contributes to the protection of blood lipids from oxidative stress and qualifies for a health claim. Overweight/obesity, characterized by excessive fat accumulation, is strongly associated with non-communicable diseases, including cardiovascular disease, type 2 diabetes, hypertension, certain cancers, and neurodegenerative disorders. Chronic low-grade inflammation and oxidative stress are key mechanisms underlying obesity-related metabolic disorders. Although dietary energy restriction remains the primary approach for weight management, growing research interest focuses on natural products rich in phenolic compounds as potential modulators of molecular pathways involved in central obesity. However, robust clinical evidence in humans with central obesity and metabolic abnormalities remains limited. Therefore, this double-blind, randomized, controlled trial aims to investigate the effects of extra virgin, high-phenolic olive oil (HPOO) compared with low-phenolic olive oil (LPOO) in adults with overweight/obesity with metabolic abnormalities. Participants will consume the assigned olive oil type (HPOO or LPOO) for eight weeks. At baseline and trial endpoint (8 weeks), data collection will include anthropometric measurements, dietary intake, biochemical indices, inflammatory and oxidative stress markers in blood samples, hormones, bioavailability of phenolic compounds, as well as lifestyle parameters i.e., health-related quality of life, physical activity levels, sleep quality. Ethical approval, informed consent, and data protection procedures will be strictly followed. Statistical analyses will be conducted using SPSS software (SPSS Inc, ΙΒΜ, Chicago, IL, USA). The study is anticipated to explore whether consumption of high-phenolic olive oil favorably modulates markers related to obesity and metabolic abnormalities, while also improving nutritional status and quality-of-life parameters.

CONDITIONS

Official Title

High Phenolic Olive Oil for Enhancing Metabolic Health: a Randomized-controlled Trial in Patients With cEntral Obesity (HOPE)

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult men and women 18-80 years of age
  • Overweight or obesity with body mass index over 25 or waist circumference over 94 cm for men and over 80 cm for women
  • Presence of at least one metabolic abnormality: triglycerides ≥150 mg/dL or low HDL cholesterol (≤40 mg/dL in men, ≤50 mg/dL in women), blood pressure ≥130/85 mm Hg, elevated fasting blood sugar ≥100 mg/dL, or standardized drug treatment for these conditions
  • Provided signed informed consent to participate
Not Eligible

You will not qualify if you...

  • Having acute or chronic diseases such as infection, cancer, chronic heart failure, kidney disease, autoimmune diseases, or inflammatory disorders
  • Untreated diabetes
  • Pregnancy or breastfeeding
  • Psychiatric or mental disorders
  • Use of antioxidant, phytochemical-rich supplements, or anti-, pre-, or probiotics before the study
  • Drug or alcohol abuse
  • Unable or unwilling to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Antikalamos Facilities of University of Peloponnese

Kalamata, Greece, 24100

Actively Recruiting

Loading map...

Research Team

A

Aristea Gioxari, Assistant Professor

CONTACT

A

Alexandra Foscolou, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here